Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focusing on the development and commercialization of innovative therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases.

Recs

0
Player Avatar pchop123 (78.31) Submitted: 1/15/2013 3:29:23 PM : Outperform Start Price: $3.30 PGNX Score: -12.33

buying on any dips

Featured Broker Partners


Advertisement